Novel biomarkers for overactive bladder

Nature Reviews Urology

Volumn 8, Issue 3, 2011, Pages 139-145

  Cartwright, Rufus ^a   Afshan, Iram ^b   Derpapas, Alexandros ^c   Vijaya, Gopalan ^c   Khullar, Vik ^c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450; CYTOKINE; DARIFENACIN; MIRABEGRON; NERVE GROWTH FACTOR; PLACEBO; PROSTAGLANDIN E2; TOLTERODINE;

BLADDER WALL; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG EFFICACY; GENE CONTROL; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HUMAN; IMAGING SYSTEM; INFLAMMATION; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; URINE INCONTINENCE; URODYNAMICS;

ANIMALS; BIOLOGICAL MARKERS; DINOPROSTONE; HUMANS; NERVE GROWTH FACTOR; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 79952697772     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.7     Document Type: Review

References (120)

1. Haylen, B. T. et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol. Urodyn. 29, 4-20 (2009).
2. Tikkinen, K. A. et al. Is the prevalence of overactive bladder overestimated? A population-based study in Finland. PLoS ONE 2, e195 (2007).
3. Lawrence, J. M., Lukacz, E. S., Nager, C. W., Hsu, J. W. & Luber, K. M. Prevalence and co-occurrence of pelvic floor disorders in community-dwelling women. Obstet. Gynecol. 111, 678-685 (2008).
4. Herschorn, S., Gajewski, J., Schulz, J. & Corcos, J. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. BJU Int. 101, 52-58 (2008).
5. Irwin, D. E. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 50, 1306-1314 (2006).
6. Temml, C., Heidler, S., Ponholzer, A. & Madersbacher, S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur. Urol. 48, 622-627 (2005).
7. Malmsten, U. G., Molander, U., Peeker, R., Irwin, D. E. & Milsom, I. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45-103 years. Eur. Urol. 58, 149-156 (2010).
8. Wehrberger, C., Temml, C., Ponholzer, A. & Madersbacher, S. Incidence and remission of female urinary incontinence over 6.5 years: analysis of a health screening project. Eur. Urol. 50, 327-332 (2006).
9. Hannestad, Y. S., Rortveit, G., Sandvik, H. & Hunskaar, S. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag. J. Clin. Epidemiol. 53, 1150-1157 (2000).
10. Homma, Y. The clinical significance of the urodynamic investigation in incontinence. BJU Int. 90, 489-497 (2002).
11. Blaivas, J. G. Overactive bladder and the definition of urgency. Neurourol. Urodyn. 26, 757-758 (2007).
12. Blaivas, J. G. Author's reply to editorial comment regarding "Overactive bladder and the definition of urgency". Neurourol. Urodyn. 26, 760 (2007).
13. Madersbacher, H. Overactive bladder: a clinical entity or a marketing hype? Eur. Urol. 47, 273-276 (2005).
14. Homma, Y. Lower urinary tract symptomatology: Its definition and confusion. Int. J. Urol. 15, 35-43 (2008).
15. Irwin, D. E., Milsom, I., Chancellor, M. B., Kopp, Z. & Guan, Z. Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review. Eur. Urol. 58, 532-543 (2010).
16. Kelleher, C. J., Cardozo, L. D., Khullar, V. & Salvatore, S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br. J. Obstet. Gynaecol. 104, 988-993 (1997).
17. Salvatore, S. et al. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur. J. Obstet. Gynecol. Reprod. Biol. 119, 237-241 (2005).
18. Lawrence, M., Guay, D. R., Benson, S. R. & Anderson, M. J. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 20, 470-475 (2000).
19. Yu, Y. F., Nichol, M. B., Yu, A. P. & Ahn, J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health 8, 495-505 (2005).
20. Brostrøm, S. & Hallas, J. Persistence of antimuscarinic drug use. Eur. J. Clin. Pharmacol. 65, 309-314 (2009).
21. Hall, S. A., Link, C. L., Hu, J. C., Eggers, P. W. & McKinlay, J. B. Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community-based sample. BJU Int. 104, 1680-1688 (2009).
22. Flisser, A. J. & Blaivas, J. G. Role of cystometry in evaluating patients with overactive bladder. Urology 60, 33-42 (2002).
23. Schäfer, W. et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressureflow studies. Neurourol. Urodyn. 21, 261-274 (2002).
24. Wyndaele, J. J. & De Wachter, S. Cystometrical sensory data from a normal population: comparison of two groups of young healthy volunteers examined with 5 years interval. Eur. Urol. 42, 34-38 (2002).
25. Sørensen, S. S., Nielsen, J. B., Nørgaard, J. P., Knudsen, L. M. & Djurhuus, J. C. Changes in bladder volumes with repetition of water cystometry. Urol. Res. 12, 205-208 (1984).
26. Erdem, E. et al. How reliable are bladder perceptions during cystometry? Neurourol. Urodyn. 23, 306-309 (2004).
27. Poulsen, E. U., Kirkeby, H. J. & Djurhuus, J. C. Short- and long-term reproducibility of cystometry. Urol. Res. 17, 197-198 (1989).
28. Erdem, E. et al. Is catheter cause of subjectivity in sensations perceived during filling cystometry? Urology 66, 1000-1003 (2005).
29. De Wachter, S., Van Meel, T. D. & Wyndaele, J. J. Can a faked cystometry deceive patients in their perception of filling sensations? A study on the reliability of spontaneously reported cystometric filling sensations in patients with non-neurogenic lower urinary tract dysfunction. Neurourol. Urodyn. 27, 395-398 (2008).
30. De Wachter, S. & Wyndaele, J. J. How sudden is a compelling desire to void? An observational cystometric study on the suddenness of this sensation. BJU Int. 101, 1000-1003 (2008).
31. Lowenstein, L. et al. Observations relating to urinary sensation during detrusor overactivity. Neurourol. Urodyn. 28, 497-500 (2009).
32. Rahmanou, P., Chaliha, C., Kulinskaya, E. & Khullar, V. Reliability testing of urodynamics, pressure flow studies and cough leak point pressure in women with urodynamic stress incontinence with and without detrusor overactivity. Int. Urogynecol. J. Pelvic Floor Dysfunct. 19, 933-938 (2008).
33. Renganathan, A., Cartwright, R., Cardozo, L., Robinson, D. & Srikrishna, S. Quality control in urodynamics: Analysis of an international multicenter study. Neurourol. Urodyn. 28, 380-384 (2009).
34. Digesu, G. A., Khullar, V., Cardozo, L. & Salvatore, S. Overactive bladder symptoms: do we need urodynamics? Neurourol. Urodyn. 22, 105-108 (2003).
35. Miller, K. L., DuBeau, C. E., Bergmann, M., Griffiths, D. J. & Resnick, N. M. Quest for a detrusor overactivity index. J. Urol. 167, 578-584 (2002).
36. Jensen, D. Jr. Terodiline treatment of detrusor hyperreflexia in sclerosis multiplex. J. Oslo City Hosp. 39, 67-73 (1989).
37. Thüroff, J. W. et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J. Urol. 145, 813-816 (1991).
38. Kabay, S. et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol. Urodyn. 28, 964-968 (2009).
39. Sahai, A. et al. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable? BJU Int. 103, 630-634 (2009).
40. Houwert, R. M. et al. Predictive value of urodynamics on outcome after midurethral sling surgery for female stress urinary incontinence. Am. J. Obstet. Gynecol. 200, 649.e1-649.e12 (2009).
41. Nager, C. W. et al. Urodynamic measures do not predict stress continence outcomes after surgery for stress urinary incontinence in selected women. J. Urol. 179, 1470-1474 (2008).
42. Malone-Lee, J. G. & Al-Buheissi, S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int. 103, 931-937 (2009).
43. Malone-Lee, J., Henshaw, D. J. & Cummings, K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int. 92, 415-417 (2003).
44. Richter, H. E. et al. Predictors of outcomes in the treatment of urge urinary incontinence in women. Int. Urogynecol. J. Pelvic Floor Dysfunct. 20, 489-497 (2009).
45. Groenendijk, P. M. et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int. 101, 325-329 (2008).
46. Nitti, V. W., Rovner, E. S. & Bavendam, T. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int. 105, 1268-1275 (2010).
47. South, M. M., Romero, A. A., Jamison, M. G., Webster, G. D. & Amundsen, C. L. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int. Urogynecol. J. Pelvic Floor Dysfunct. 18, 1395-1398 (2007).
48. Nager, C. W. et al. Design of the Value of Urodynamic Evaluation (ValUE) trial: a noninferiority randomized trial of preoperative urodynamic investigations. Contemp. Clin. Trials 30, 531-539 (2009).
49. Buchsbaum, G. M., Albushies, D. T. & Guzick, D. S. Utility of urine reagent strip in screening women with incontinence for urinary tract infection. Int. Urogynecol. J. Pelvic Floor Dysfunct. 15, 391-393 (2004).
50. Khasriya, R. et al. The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. J. Urol. 183, 1843-1847 (2010).
51. Tyagi, P. et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int. Urol. Nephrol. 42, 629-635 (2010).
52. Anderson, G. F. & Kohn, K. I. Interactions of calcium, prostaglandins and indomethacin on the smooth muscle of the bladder. Pharmacology 16, 306-313 (1978).
53. Klarskov, P., Gerstenberg, T., Ramirez, D., Christensen, P. & Hald, T. Prostaglandin type E activity dominates in urinary tract smooth muscle in vitro. J. Urol. 129, 1071-1074 (1983).
54. Schüssler, B. Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. A urodynamic study. Urol. Res. 18, 349-352 (1990).
55. Ishizuka, O., Mattiasson, A. & Andersson, K. E. Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins? J. Urol. 153, 2034-2038 (1995).
56. Yokoyama, O. et al. Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure. J. Urol. 178, 2208-2212 (2007).
57. Takeda, H. et al. Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol. Urodyn. 21, 558-565 (2002).
58. Masunaga, K. et al. Prostaglandin E2 release from isolated bladder strips in rats with spinal cord injury. Int. J. Urol. 13, 271-276 (2006).
59. Shioyama, R. et al. Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295, R714-R718 (2008).
60. Kim, J. C. et al. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int. J. Urol. 12, 875-880 (2005).
61. Kim, J. C., Park, E. Y., Seo, S. I., Park, Y. H. & Hwang, T. K. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J. Urol. 175, 1773-1776 (2006).
62. Aoki, K. et al. A higher level of prostaglandin E2 in the urinary bladder in young boys and boys with lower urinary tract obstruction. Biomed. Res. 30, 343-347 (2009).
63. Liu, H. T., Tyagi, P., Chancellor, M. B. & Kuo, H. C. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int. 106, 1681-1685 (2010).
64. Dmitrieva, N. & McMahon, S. B. Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 66, 87-97 (1996).
65. Spitsbergen, J. M., Clemow, D. B., McCarty, R., Steers, W. D. & Tuttle, J. B. Neurally mediated hyperactive voiding in spontaneously hypertensive rats. Brain Res. 790, 151-159 (1998).
66. Oddiah, D., Anand, P., McMahon, S. B. & Rattray, M. Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder. Neuroreport 9, 1455-1458 (1998).
67. Steers, W. D., Kolbeck, S., Creedon, D. & Tuttle, J. B. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J. Clin. Invest. 88, 1709-1715 (1991).
68. Lowe, E. M. et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br. J. Urol. 79, 572-577 (1997).
69. Tanner, R., Chambers, P., Khadra, M. H. & Gillespie, J. I. The production of nerve growth factor by human bladder smooth muscle cells in vivo and in vitro. BJU Int. 85, 1115-1119 (2000).
70. Liu, H. T. & Kuo, H. C. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 72, 104-108 (2008).
71. Yokoyama, T., Kumon, H. & Nagai, A. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol. Urodyn. 27, 417-420 (2008).
72. Liu, H. T., Chancellor, M. B. & Kuo, H. C. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int. 102, 1440-1444 (2008).
73. Liu, H. T., Chen, C. Y. & Kuo, H. C. Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int. doi:10.1111/j.1464-410X.2010. 09585.x.
74. Liu, H. T., Chancellor, M. B. & Kuo, H. C. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int. 103, 1668-1672 (2009).
75. Jacobs, B. L. et al. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can. J. Urol. 17, 4989-4994 (2010).
76. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [online], http://www.clinicaltrials.gov/ct2/show/ NCT01093534 (2011).
77. Saxton, H. M., Borzyskowski, M., Mundy, A. R. & Vivian, G. C. Spinning top urethra: not a normal variant. Radiology 168, 147-150 (1988).
78. Batista, J. E., Caffaratti, J., Arañó, P., Regalado, R. & Garat, J. M. The reliability of cysto-urethrographic signs in the diagnosis of detrusor instability in children. Br. J. Urol. 81, 900-904 (1998).
79. Athanasiou, S., Khullar, V., Boos, K., Salvatore, S. & Cardozo, L. Imaging the urethral sphincter with three-dimensional ultrasound. Obstet. Gynecol. 94, 295-301 (1999).
80. Digesu, G. A., Robinson, D., Cardozo, L. & Khullar, V. Three-dimensional ultrasound of the urethral sphincter predicts continence surgery outcome. Neurourol. Urodyn. 28, 90-94 (2009).
81. Pirpiris, A., Shek, K. L. & Dietz, H. P. Urethral mobility and urinary incontinence. Ultrasound Obstet. Gynecol. 36, 507-511 (2010).
82. Khullar, V. et al. A novel technique for measuring bladder wall thickness in women using transvaginal ultrasound. Ultrasound Obstet. Gynecol. 4, 220-223 (1994).
83. Panayi, D. C., Tekkis, P., Fernando, R., Hendricken, C. & Khullar, V. Ultrasound measurement of bladder wall thickness is associated with the overactive bladder syndrome. Neurourol. Urodyn. 29, 1295-1298 (2010).
84. Oelke, M., Höfner, K., Wiese, B., Grünewald, V. & Jonas, U. Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men. World J. Urol. 19, 443-452 (2002).
85. Yang, J. M. & Huang, W. C. Bladder wall thickness on ultrasonographic cystourethrography: affecting factors and their implications. J. Ultrasound Med. 22, 777-782 (2003).
86. Serati, M. et al. Ultrasound measurement of bladder wall thickness in different forms of detrusor overactivity. Int. Urogynecol. J. Pelvic Floor Dysfunct. 21, 1405-1411 (2010).
87. Kuhn, A. et al. Sonographic transvaginal bladder wall thickness: Does the measurement discriminate between urodynamic diagnoses? Neurourol. Urodyn. doi:10.1002/nau.20997.
88. Panayi, D. C., Khullar, V., Fernando, R. & Tekkis, P. Transvaginal ultrasound measurement of bladder wall thickness: a more reliable approach than transperineal and transabdominal approaches. BJU Int. 106, 1519-1522 (2010).
89. Cvitkovic-Kuzmic, A., Brkljacic, B., Ivankovic, D. & Grga, A. Ultrasound assessment of detrusor muscle thickness in children with non-neuropathic bladder/sphincter dysfunction. Eur. Urol. 41, 214-218 (2002).
90. Müller, L., Bergström, T., Hellström, M., Svensson, E. & Jacobsson, B. Standardized ultrasound method for assessing detrusor muscle thickness in children. J. Urol. 164, 134-138 (2000).
91. Vrljicak, K., Milosevic, D., Batinic, D., Kniewald, H. & Nizic, L. The significance of ultrasonography in diagnosing and follow-up of cystic cystitis in children. Coll. Antropol. 30, 355-359 (2006).
92. Yang, J. M. & Huang, W. C. Discrimination of bladder disorders in female lower urinary tract symptoms on ultrasonographic cystourethrography. J. Ultrasound Med. 21, 1249-1255 (2002).
93. Chung, S. D. et al. Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int. 105, 668-672 (2010).
94. Kuo, H. C., Liu, H. T. & Chancellor, M. B. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol. Urodyn. 29, 482-487 (2010).
95. Latthe, P. M., Champaneria, R. & Khan, K. S. Systematic review of the accuracy of ultrasound as the method of measuring bladder wall thickness in the diagnosis of detrusor overactivity. Int. Urogynecol. J. Pelvic Floor Dysfunct. 21, 1019-1024 (2010).
96. Bright, E., Oelke, M., Tubaro, A. & Abrams, P. Ultrasound estimated bladder weight and measurement of bladder wall thickness-useful noninvasive methods for assessing the lower urinary tract? J. Urol. 184, 1847-1854 (2010).
97. Oelke, M. International Consultation on Incontinence-Research Society (ICI-RS) report on non-invasive urodynamics: the need of standardization of ultrasound bladder and detrusor wall thickness measurements to quantify bladder wall hypertrophy. Neurourol. Urodyn. 29, 634-639 (2010).
98. Kojima, M. et al. Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: a preliminary report. Urology 47, 942-947 (1996).
99. Panayi, D. C. et al. Is ultrasound estimation of bladder weight a useful tool in the assessment of patients with lower urinary tract symptoms? Int. Urogynecol. J. Pelvic Floor Dysfunct. 20, 1445-1449 (2009).
100. Kojima, M. et al. Reversible change of bladder hypertrophy due to benign prostatic hyperplasia after surgical relief of obstruction. J. Urol. 158, 89-93 (1997).
101. Griffiths, D., Derbyshire, S., Stenger, A. & Resnick, N. Brain control of normal and overactive bladder. J. Urol. 174, 1862-1867 (2005).
102. Pontari, M. A. et al. Central nervous system findings on functional magnetic resonance imaging in patients before and after treatment with anticholinergic medication. J. Urol. 183, 1899-1905 (2010).
103. Hannestad, Y. S., Lie, R. T., Rortveit, G. & Hunskaar, S. Familial risk of urinary incontinence in women: population based cross sectional study. BMJ 329, 889-891 (2004).
104. Buchsbaum, G. M., Duecy, E. E., Kerr, L. A., Huang, L. S. & Guzick, D. S. Urinary incontinence in nulliparous women and their parous sisters. Obstet. Gynecol. 106, 1253-1258 (2005).
105. Rohr, G., Kragstrup, J., Gaist, D. & Christensen, K. Genetic and environmental influences on urinary incontinence: a Danish population-based twin study of middle-aged and elderly women. Acta Obstet. Gynecol. Scand. 83, 978-982 (2004).
106. Altman, D., Forsman, M., Falconer, C. & Lichtenstein, P. Genetic influence on stress urinary incontinence and pelvic organ prolapse. Eur. Urol. 54, 918-922 (2008).
107. Eiberg, H., Shaumburg, H. L., Von Gontard, A. & Rittig, S. Linkage study of a large Danish 4-generation family with urge incontinence and nocturnal enuresis. J. Urol. 166, 2401-2403 (2001).
108. Loeys, B. et al. Does monosymptomatic enuresis exist? A molecular genetic exploration of 32 families with enuresis/incontinence. BJU Int. 90, 76-83 (2002).
109. Honda, K., Nomiya, M., Shishido, K., Yoshimura, Y. & Yamaguchi, O. Mutation of beta 3-adrenoceptor gene: a genetic marker for overactive bladder [abstract]. Neurourol. Urodyn. 25, 652 (2006).
110. Yamaguchi, O. & Chapple, C. R. Beta3-Adrenoceptors in urinary bladder. Neurourol. Urodyn. 26, 752-756 (2007).
111. Tyagi, P., Tyagi, V., Yoshimura, N., Chancellor, M. & Yamaguchi, O. Beta3-adrenoceptor agonists for the treatment of overactive bladder. Drugs Fut. 34, 635 (2009).
112. Leineweber, K., Büscher, R., Bruck, H. & Brodde, O. E. Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol. 369, 1-22 (2004).
113. Zanger, U. M., Turpeinen, M., Klein, K. & Schwab, M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392, 1093-1108 (2008).
114. Kerbusch, T., Wählby, U., Milligan, P. A. & Karlsson, M. O. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br. J. Clin. Pharmacol. 56, 639-652 (2003).
115. Skerjanec, A. The clinical pharmacokinetics of darifenacin. Clin. Pharmacokinet. 45, 325-350 (2006).
116. Diefenbach, K. et al. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. Sleep Med. 9, 579-582 (2008).
117. Serra, D. B. et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J. Clin. Pharmacol. 45, 1038-1047 (2005).
118. Norton, P. & Milsom, I. Genetics and the lower urinary tract. Neurourol. Urodyn. 29, 609-611 (2010).
119. Cartwright, R. et al. Whole genome gene expression in bladder tissue from women with detrusor overactivity [abstract]. Neurourol. Urodyn. 29, 981-982 (2010).
120. Cheung, W. et al. Peripheral blood mononuclear cell gene array profiles in patients with overactive bladder. Urology 75, 896-901 (2010).